Jeffrey Richard Thill, M.D North Mills Avenue Orlando, FL 32803
|
|
- Merry George
- 6 years ago
- Views:
Transcription
1 Jeffrey Richard Thill, M.D North Mills Avenue Orlando, FL CURRENT POSITION AFFILIATIONS BIRTHPLACE BOARD CERTIFIED UROLOGIST WINTER PARK UROLOGY ASSOCIATES, P.A NORTH MILLS AVENUE, ORLANDO, FL Present STAFF UROLOGIST, WINTER PARK MEMORIAL HOSPITAL STAFF UROLOGIST, FLORIDA HOSPITAL, ORLANDO CLINICAL PROFESSOR OF UROLOGY, SHANDS HOSPITAL UNIVERSITY OF FLORIDA CLINICAL ASSISTANT PROFESSOR FLORIDA STATE UNIVERSITY SCHOOL OF MEDICINE MEMBER, ORANGE COUNTY MEDICAL SOCIETY MEMBER, FLORIDA MEDICAL ASSOCIATION MEMBER, AMERICAN UROLOGICAL ASSOCIATION KANSAS CITY, MISSOURI AUGUST 1, 1962 FAMILY STATUS MARRIED TO KARIN BUTTON THILL, R.N., 1983 ONE CHILD, LEVI, BORN APRIL 2, 1985 EDUCATION B.A., MCPHERSON COLLEGE UNIVERSITY OF IOWA M.D., UNIVERSITY OF IOWA POST-GRADUATE GENERAL SURGERY UNIVERSITY OF FLORIDA JULY 1988-JUNE 1990 DEPARTMENT OF UROLOGY UNIVERSITY OF FLORIDA JULY LICENSURE FLORIDA #ME FLEX 1989 IN-TRAINING EXAMINATIONS UROLOGY TH PERCENTILE UROLOGY RD PERCENTILE UROLOGY TH PERCENTILE AWARDS SUMMA CUM LAUDE-MCPHERSON COLLEGE 1984 RECOGNITIONS UROLOGY FOUNDATION IN-SERVICE AWARD 1991, 1992 WISE OWL AWARD, FLORIDA UROLOGIC SOCIETY TARPON SPRINGS, FL, 1991 UNIVERSITY OF FLORIDA UROLOGY RESEARCH AWARD,
2 MEMBERSHIPS FLORIDA MEDICAL ASSOCIATION AMERICAN MEDICAL ASSOCIATION FLORIDA UROLOGICAL SOCIETY AMERICAN UROLOGICAL ASSOCIATION SOCIETY OF LAPAROENDOSCOPIC SURGEONS PUBLICATIONS "EFFECTS OF THE ANTIMITOCHONDRIAL AGENTS PRESENTATIONS LONIDAMINE AND DOXYCYCLINE AGAINST HUMAN RENAL CARCINOMA CELLS" PRESENTATION AT AMERICAN ASSOCIATION FOR CANCER RESEARCH, NEW ORLEANS, LA, MAY 1988 "WHAT'S THE CAUSE OF ABNORMALLY COLORED URINE" M. S. COHEN AND J. R. THILL, CONTEMPORARY UROLOGY, JUNE 1992 "ANTENATAL BLADDER RUPTURE: A COMPLICATION OF INTERVENTION FOR OBSTRUCTIVE UROPATHY" J. R. THILL AND R. D. WALKER, PRESENTATION AT SOUTHEASTERN SECTION, APRIL 1993, NASHVILLE, TN Research A Randomized, Double-Blind, Comparative Trial of a Study Drug Versus Placebo in Patients with Early Prostate Cancer A Randomized, Double-Blind, Placebo-Controlled, Two Year Parallel Group Study of the Efficacy and Safety of Study Drug 0.5 Mg in the Treatment and Prevention of Progression of Benign Prostatic Hyperplasia A Phase III Efficacy and Safety Study Comparing Escalating Doses of Study Drug to 5 mg or 6 mg Doses of Study Drug or Placebo in the Treatment of Male Erectile Dysfunction A Study to Evaluate the Impact of Study Drug on Treatment Satisfaction A Phase III, Long-Term, Open-Label, Flexible Dose, and Safety Extension Study of Study Drug in the Treatment of Male Erectile Dysfunction A Phase III at Home Use Study Evaluating the Efficacy and Safety of Escalating Doses of Study Drug 2, 3, and 4 mg in the Treatment with Erectile Dysfunction A Study to Evaluate the Efficacy and Safety of a Study Drug Versus Placebo in Subjects with Overactive 2
3 Bladder A Phase III, Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel Group Study of the Efficacy and Safety of a Controlled Release Study Drug Versus A Study Drug in the Treatment of Subjects with Overactive Bladder A Randomized, Parallel Group, Double-Blind, Placebo-Controlled Study Comparing the Safety, Tolerance, and Efficacy of a Study Drug in Patients with Detrusor Hyperreflexia A Randomized, Double-Blind, Multi-Centre, Fixed Dose, Parallel-Group Twelve Month Study to Investigate the Safety and Tolerability of a Study Drug in the Treatment of Patients with Erectile Dysfunction A phase III, Randomized, Multicenter, Placebo Controlled, Double-Blind Clinical Trial to Study the Efficacy and Safety of Study Drug for the Treatment of Hot Flashes Following Surgical of Chemical Castration of Prostate Cancer Patients and Its Impact on the Quality of Life in These Patients A Phase IV, Open-label, Multi-Center, Large Community Based Study with an Eight Week Treatment Period to Evaluate the Satisfaction and Experience with Replacement Therapy A Phase IV, Open-Label, Multicenter, Community- Based Trial of Study Drug for the Treatment of Urogenital Symptoms in Postmenopausal Women A Patient Acceptability Study of a Once-Daily Formulation of Study Drug. A Phase IIIB, Open- Label, Single-Arm Trial in Adult Patients With Overactive Bladder and Symptoms of Urinary Frequency, Urgency, and/or Urge Incontinence A Multicenter Trial of Induction and 6 Courses of 3 Week Maintenance With BCG Versus BCG Plus Interferon Alfa-2B (Intron A) In Superficial Bladder Cancer A Multi-center, Multinational Open Clinical Study to Explore Relationships between Genotypic 3
4 (from DNA) and Serologic (from serum) Findings and Phenotypic Manifestations in a Large Cohort of Participants A Phase IIb/III Chemoprevention Trial of Study Drug to Prevent the Recurrence of Superficial Bladder Cancer Prospective, Randomized, Double-Blind Multi- Center, Fixed Dose, Parallel-Group Twelve Month Extension of Study XXXXX to Investigate the Safety and Tolerability of the Study Drug in the Treatment of Patients with Erectile Dysfunction over a Total Exposure Time of 24 Months A Phase III, Double-Blind, Randomized, Parallel Study Evaluating the Safety and Efficacy of Study Drug in the Treatment of Male Erectile Dysfunction Double-Blind, Placebo Controlled Study of Sustained Release Study Drug in Subjects with Symptoms of Overactive Bladder of Urgency, Frequency and Urinary Incontinence An Investigation Of The NMP22 Point of Care POC) Device As An Aid In The Monitoring Of Bladder Cancer Patients An Investigation Of The NMP22 Point Of Care POC) Device As An Aid In The Screening Of Patients At Risk For Bladder Cancer A Phase 3B, Multi-Center, Double-Blind, Randomized, Placebo-Contolled, Parallel Group Study of Study Drug in Subjects with Overactive Bladder A Multicenter, Phase IIB, Four Arm, Dose Finding, Randomized, Placebo-Controlled Study to Determine the Long Term Prostate Cancer Chemoprevention Efficacy and Safety of 20mg, 40mg & 60mg Daily of Study Drug in Men With High Grade Prostate Intraepithelial Neoplasia (PIN) An Open-Label, Multicenter, Multinational Study to Determine the Safety and Efficacy of Study Drug Oral Solution in Children with Symptoms of Urge Urinary Incontinence Suggestive of Detrusor Instability An Open-label Trial on the Effect of IV Study Drug 4
5 4mg on Bone Mineral Density in Hormone Sensitive Prostate Cancer Patients with Bone Metastasis A Randomized, Double-Blind, Parallel Group, Multi-center Study to Investigate the Time to Onset of Action of 20 mg Study Drug Compared to Placebo in Males with Erectile Dysfunction A Double-Blind, Placebo-Controlled, Randomized, US/Latin America Study to Evaluate the Effect of Study Drug Prolonged Release on Nocturia in Patients with Symptoms of Overactive Bladder (OAB) A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Study Drug 0.5mg Administered Once Daily for Four Years to Reduce the Risk Of Biopsy-Detectable Prostate Cancer 2003-present A Double-Blind, Placebo-Controlled Study of Frequency and Urgency Using Study Drug 20mg Tablets, Twice Daily, For 12 Weeks Followed by a 6-Month Open-Label Treatment Phase in Patients With Overactive Bladder A Multicenter, Open-Label, Flexible Dose Study to Investigate the Use Pattern of Viagra (sildenafil citrate) And The Ability of Investigators To Further Optimize Subject Satisfaction With Viagra Through Customized Instruction Open-Label Study of the Efficacy and Safety of 5mg and 10mg Study Drug in Patients with Overactive Bladder Symptoms An Open-Label Study to Evaluate the Efficacy and Safety of Study Drug Administered On Demand to Men of Various Populations with Erectile Dysfunction A Randomized, Double-Blind, Placebo-Controlled, Multicenter Efficacy and Safety Study of Study Drug for the Prevention Of Bone Fractures in Men with Prostate Cancer on Androgen Deprivation Therapy 2003-present REALISE: Real Life Safety and Efficacy with Levitra JEFFREY R. THILL,M.D. A Phase 3, Parallel Group, Randomized, Double-Blind, Placebo-Controlled Multicenter Trial to Investigate the Efficacy, Tolerability and Safety of Study Drug Sustained Release in Subjects with Overactive Bladder Syndrome 2003-present Study of Study Drug in Women of Different Demographic 5
6 Characteristics and Co-morbidities with Stress Urinary Incontinence: Evaluation of Efficacy and Safety 2003-present A Study to Compare the Safety and Efficacy of Once Daily Study Drug Versus Twice Daily Study Drug in the Treatment of Complicated Urinary Tract Infection and Acute Pyelonephritis A Double-Blind, Randomized, Placebo-Controlled Trial of Elmiron For The Treatment of Chronic, Non- Bacterial Prostatitis A Randomized, Double-Blind, Crossover Study to Evaluate the Duration of Erection following Study Drug 10mg Administration for 4 Weeks in a Fixed-Dose Regimen Compared to Placebo In Males with ED An Open-Label, Multicenter Study to Assess the Efficacy and Safety of Daily Oral Administration of 5 and 10mg Study Drug in Patients Who Wish to Switch from Detrol LA for the Treatment of OveractiveBladder Symptoms Prospective, Observational Registry and Patient Survey of the Management of Men with Symptomatic Benign Prostatic Hyperplasia A Placebo-Controlled, Double-Blind, Randomized, Parallel Study of the Withdrawal Effects of Chronic Daily and As Needed Dosing with Study Drug in the Treatment of Premature Ejaculation 2005-present A Multicenter, 2 Week, Double-Blind Study of XXXX 60mg QD Modified Release Capsules and Placebo Given Once Daily In The Morning of In The Evening In Patients with Overactive Bladder 2005-present JEFFREY R. THILL,M.D. A Randomized, Double-Blind, Placebo-Controlled, Multicenter Efficacy and Safety Study of XXXX for the Prevention of Prostate Cancer in Men with High Grade Prostate Intraepithelial Neoplasia 2005-present 6
7 Updated 2/2005 7
David Henry Jablonski, M.D North Mills Avenue Orlando, FL 32803
David Henry Jablonski, M.D. 1812 North Mills Avenue Orlando, FL 32803 EDUCATION: University of Florida College of Medicine, Gainesville, Florida Division of Urology Residency Training Program July 1994-June
More informationGary Scott Friedlander, M.D. Urological Consultants, P.A. A Division of Chesapeake Urology Associates, LLC
Gary Scott Friedlander, M.D. Urological Consultants, P.A. A Division of Chesapeake Urology Associates, LLC 9420 Key West Ave, Suite 420, Rockville, MD 20850 2730 University Blvd, West, Suite 516, Wheaton,
More informationOffice based non-oncology urology trials Richard W. Casey, MD, 1 Jack Barkin, MD 2
Office based non-oncology urology trials Richard W. Casey, MD, 1 Jack Barkin, MD 2 1 The Male Health Centre, Oakville, Ontario, Canada 2 Humber River Regional Hospital, University of Toronto, Toronto,
More informationH6D-MC-LVHR Clinical Study Report Synopsis Page LVHR Synopsis (LY450190)
H6D-MC-LVHR Clinical Study Report Synopsis Page 1 2. LVHR Synopsis H6D-MC-LVHR Clinical Study Report Synopsis Page 2 Clinical Study Report Synopsis: Study H6D-MC-LVHR Title of Study: A Randomized, Double-Blind,
More informationStudy No. 178-CL-008 Report Final Version, 14 Dec 2006 Reissued Version, 18 Jul 2011 Astellas Pharma Europe B.V. Page 13 of 122
Page 13 of 122 3 SYNOPSIS Title of study: (International) Study No: A randomized, double-blind, parallel group, proof-of-concept study of in comparison with placebo and tolterodine in patients with symptomatic
More informationCurriculum Vitae, Conrad O. Beckles, M.S., L.M.H.C., Ph.D.
CONTACT INFORMATION: Site Selection and Information: Bobbie Theodore, Alliance Director Tel. (916) 939-6696 Fax (208) 575-3169 Email: clinicaltrials@alliancesites.com AFFILIATIONS: Conrado Oscar Beckles,
More informationCENTENE PHARMACY AND THERAPEUTICS DRUG REVIEW 3Q17 July-August
BRAND NAME Noctiva GENERIC NAME Desmopressin acetate nasal spray MANUFACTURER Serenity Pharmaceuticals DATE OF APPROVAL March 3, 2017 PRODUCT LAUNCH DATE TBD REVIEW TYPE Review type 1 (RT1): New Drug Review
More informationRichard J. Ingebretsen, M.D., Ph.D.
Richard J. Ingebretsen, M.D., Ph.D. 3755 Sunnydale Lane - Emigration Canyon, Utah 84108 (801) 554-2124 richi47@comcast.net EDUCATION 1993 M.D. - University of Utah School of Medicine 1989 Ph.D. - University
More informationMAZE MEN S SEXUAL & REPRODUCTIVE HEALTH CURRICULUM VITAE
MAZE MEN S SEXUAL & REPRODUCTIVE HEALTH CURRICULUM VITAE NAME Michael A. Werner, M.D. TITLE Medical Director, Maze Sexual & Reproductive Health Board certified urologist with practice limited to Sexual
More informationUV-2005/01. Chronic Prostatitis and Chronic Pelvic Pain Syndrom (CP/CPPS) Karl-Bickleder-Str. 44C Straubing - Germany
SYNOPSIS UV-2005/01 Title: Short Title: Indication: Phase: Study Code: Study Director Co-ordinating Investigator: Study Centres: Multicentre, randomised, double-blind, placebo-controlled clinical study
More informationUTILITY OF NMP22 BLADDERCHEK POINT-OF- CARE ASSAY IN EVALUATION OF HEMATURIA: A MULTICENTER STUDY
UTILITY OF NMP22 BLADDERCHEK POINT-OF- CARE ASSAY IN EVALUATION OF HEMATURIA: A MULTICENTER STUDY Giora Katz* M.D. Lakeshore Urology manitowoc WI, and the NMP22 Clinical Investigation Group. Author Disclosure
More informationIndex. Note: Page numbers of article titles are in boldface type.
Urol Clin N Am 31 (2004) 379 387 Index Note: Page numbers of article titles are in boldface type. A Acinar proliferation, atypical small, as markers for risk of development of prostate cancer, 229 Acupuncture,
More informationSteven M. Weiner, M.D.
Steven M. Weiner, M.D. EDUCATION University of Colorado, Denver, CO., 1983 M.D. University of Michigan, Ann Arbor, MI., 1978 B.S. in Chemistry and Cellular Biology Thesis: N.N -Diacetylcystine(DAC): A
More informationJune 15, Proprietary blending concept for Natural Bladder Support for Women & Men
June 15, 2011 Proprietary blending concept for Natural Bladder Support for Women & Men Go Less to the Toilet For what stands? GoLess is a registered concept for urinary health which stands for 3 different
More information09/84-06/88 BA, Chemistry Robert D. Clark Honors College, University of Oregon, Eugene, OR
CONTACT INFORMATION: Drissana T Tran, M.D. Oregon Center for Clinical Investigations, Inc. 702 Church Street NE Salem, OR 97301 Site Selection and Information: Bobbie Theodore, Alliance Director Tel. (916)
More informationPACIFIC RESEARCH NETWORK_ 3003 Fourth Avenue, San Diego, CA * (619) Ph. (619) Fax
PACIFIC RESEARCH NETWORK 3003 Fourth Avenue, San Diego, CA 92103 * (619) 294-4302 Ph. (619) 294-4867 Fax JOHN J. DORIA, M.D. EDUCATION 1958 Medical: Universidad Nationale de Mexico, Mexico, Degree: M.
More informationCurriculum Vitae, Edward H. Ortiz, M.D.
CONTACT INFORMATION: Site Selection and Information: Bobbie Theodore, Alliance Director Tel. (916) 939-6696 Fax (208) 575-3169 Email: clinicaltrials@alliancesites.com AFFILIATIONS: FutureSearch Trials
More informationAn Undergraduate Syllabus for Urology. Produced on behalf of the British Association of Urological Surgeons. March 2012
An Undergraduate Syllabus for Urology Produced on behalf of the British Association of Urological Surgeons March 2012 Authors H Hashim, P Jones, KJ O Flynn, I Pearce, J Royle, M Shaw, AM Sinclair Correspondence
More informationA SURVEY ON LOWER URINARY TRACT SYMPTOMS (LUTS) AMONG PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA (BPH) IN HOSPITAL UNIVERSITI SAINS MALAYSIA (HUSM)
Malaysian Journal of Medical Sciences, Vol. 14, No. 2, July 2007 (67-71) SHORT COMMUNICATION A SURVEY ON LOWER URINARY TRACT SYMPTOMS (LUTS) AMONG PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA (BPH) IN HOSPITAL
More informationD-MANNOSE, CRANBERRY AND VITAMIN C (CYSTOMAN 100MG) ARE EFFECTIVE IN PREVENTING URINARY TRACT INFECTIONS IN MULTIPLE SCLEROSIS SUBJECTS.
D-MANNOSE, CRANBERRY AND VITAMIN C (CYSTOMAN 100MG) ARE EFFECTIVE IN PREVENTING URINARY TRACT INFECTIONS IN MULTIPLE SCLEROSIS SUBJECTS. Maria Laura Lopes De Carvalho, MD Guido Francavilla, MD Roberta
More informationMANAGING BENIGN PROSTATIC HYPERTROPHY IN PRIMARY CARE DR GEORGE G MATHEW CONSULTANT FAMILY PHYSICIAN FELLOW IN SEXUAL & REPRODUCTIVE HEALTH
MANAGING BENIGN PROSTATIC HYPERTROPHY IN PRIMARY CARE DR GEORGE G MATHEW CONSULTANT FAMILY PHYSICIAN FELLOW IN SEXUAL & REPRODUCTIVE HEALTH INTRODUCTION (1) Part of male sexual reproductive organ Size
More informationCURRICULUM VITAE. Andrea Marraffino, Ph.D.
CURRICULUM VITAE CONTACT INFORMATION: Site Selection and Information: Bobbie Theodore, Site Liaison Tel. (866) 669-0234 Fax (208) 575-3169 Email: clinicaltrials@btheodore.com AFFILIATIONS: Florida Clinical
More informationEVALUATION OF THE EFFICACY OF TADALAFIL IN IMPROVING LOWER URINARY TRACT SYMPTOMS IN PATIENTS WITH SYMPTOMATIC BENIGN PROSTATIC ENLARGEMENT
Basrah Journal Of Surgery EVALUATION OF THE EFFICACY OF TADALAFIL IN IMPROVING LOWER URINARY TRACT SYMPTOMS IN PATIENTS WITH SYMPTOMATIC BENIGN PROSTATIC ENLARGEMENT MB, ChB, FIBMS, Assistant Professor
More informationMoving Beyond Cancer To A New Normal in Intimacy For Men & Their Partners. Presented by Mary Ellen West, RN, MN, CNM AASECT Certified Sex Counselor
Moving Beyond Cancer To A New Normal in Intimacy For Men & Their Partners Presented by Mary Ellen West, RN, MN, CNM AASECT Certified Sex Counselor WHO Definition of Sexuality Central aspect of being human
More informationThe Royal Marsden. Prostate case study. Presented by Mr Alan Thompson Consultant Urological Surgeon
Prostate case study Presented by Mr Alan Thompson Consultant Urological Surgeon 2 Part one Initial presentation A 62 year old male solicitor attends your GP surgery. He has rarely seen you over the last
More informationBenign Prostatic Hyperplasia. Jay Lee, MD, FRCSC Clinical Associate Professor University of Calgary
Benign Prostatic Hyperplasia Jay Lee, MD, FRCSC Clinical Associate Professor University of Calgary Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied,
More informationAUCKLAND REGIONAL UROLOGY GUIDELINES AND REFERRAL RECOMMENDATIONS
AUCKLAND REGIONAL UROLOGY GUIDELINES AND REFERRAL RECOMMENDATIONS This document outlines the urological conditions currently funded at Auckland District Health Board (ADHB), Counties Manukau District Health
More informationUROLOGY ROTATION SYLLABUS. Level of Training PGY3. Length of Rotation Longitudinal during Geriatric Block Rotation. Preceptors Name(s) and Titles
UROLOGY ROTATION SYLLABUS Level of Training PGY3 Length of Rotation Longitudinal during Geriatric Block Rotation Preceptors Name(s) and Titles David Miles, M.D. Contact s Name Dr. Ed Forster 431-5714 Beeper
More informationSome prostatic diseases
Some prostatic diseases Benign Prostatic Hyperplasia (Nodular Hyperplasia) Extremely common Present in a significant number of men by the age of 40 & its frequency rises progressively with age, reaching
More informationUrinary tract disorders
Urinary tract disorders Medicines Formulary Contents: 1. Urinary retention 1 2. Urinary incontinence 2 3. Urethral pain prevention during catheterisation 3 4. Indwelling catheters maintenance of patency
More informationPatient Expectations Following Greenlight XPS
Patient Expectations Following Greenlight XPS 1. Hematuria it is common for men to have light pink to cherry red urine following the procedure. This small amount of blood in the urine usually resolves
More informationNational Cancer Institute of Canada Clinical Trials Group (NCIC CTG) Trial design:
Open clinical uro-oncology trials in Canada Eric Winquist, MD, Mary J. Mackenzie, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada BLADDER CANCER A PHASE III STUDY OF IRESSA
More informationOpen clinical uro-oncology trials in Canada
Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer A PHASE II PROTOCOL FOR PATIENTS WITH STAGE T1
More informationShelileah R. Newman. Certifications. Education. Work history. Board Certified. Licensure. Undergraduate / Bachelor of Science.
Shelileah R. Newman Certifications Board Certified Certified by The American Board of Radiology, 2009 Licensure North Carolina - Full and Unrestricted MD License, Number 2004-01566. Florida - Full and
More informationOpen clinical uro-oncology trials in Canada
Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer A PHASE II PROTOCOL FOR PATIENTS WITH STAGE T1
More informationCurriculum Vitae, Lara Goenjian Shirikjian, D.O. Lara Goenjian Shirikjian, D.O. Collaborative Neuroscience Network, LLC
CONTACT INFORMATION: Site Selection and Information: Bobbie Theodore, Alliance Director Tel. (916) 939-6696 Fax (208) 575-3169 Email: clinicaltrials@alliancesites.com AFFILIATIONS: Collaborative Neuroscience
More informationURINARY INCONTINENCE. Urology Division, Surgery Department Medical Faculty, University of Sumatera Utara
URINARY INCONTINENCE Urology Division, Surgery Department Medical Faculty, University of Sumatera Utara Definition The involuntary loss of urine May denote a symptom, a sign or a condition Symptom the
More informationOpen clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD
Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada BLADDER CANCER A MULTICENTRE, RANDOMIZED PLACEBO-CONTROLLED, DOUBLE-BLIND
More informationChapter 4: Research and Future Directions
Chapter 4: Research and Future Directions Introduction Many of the future research needs listed in the 1994 Agency for Health Care Policy and Research (AHCPR) clinical practice guideline Benign Prostatic
More informationClinicalTrials.gov Protocol Registration and Results System (PRS) Receipt Release Date: 10/11/2013. ClinicalTrials.gov ID: NCT
ClinicalTrials.gov Protocol Registration and Results System (PRS) Receipt Release Date: 10/11/2013 ClinicalTrials.gov ID: NCT00168454 Study Identification Unique Protocol ID: 191622-077 Brief Title: A
More informationPaula J. Lane, M.D. Albuquerque Neuroscience, Inc. 101 Hospital Loop NE, Suite 209 Albuquerque, NM 87109
CONTACT INFORMATION: Site Selection and Information: Bobbie Theodore, Alliance Director Tel. (916) 939-6696 Fax (208) 575-3169 Email: clinicaltrials@alliancesites.com EDUCATION: Paula J. Lane, M.D. Albuquerque
More informationClinical Trial Study Synopsis
Clinical Trial Study Synopsis This file is posted on the Bayer HealthCare Clinical Trials Registry and Results website and is provided for patients and healthcare professionals to increase the transparency
More informationLUNCH AND LEARN. April 17, 2018 David R. Wilkinson M.D. Gulfshore Urology
LUNCH AND LEARN April 17, 2018 David R. Wilkinson M.D. Gulfshore Urology Medical Therapy for Prostate Cancer Androgen (testosterone) is required for the growth of both normal prostate and prostate cancers
More informationThe Enlarged Prostate Symptoms, Diagnosis and Treatment
The Enlarged Prostate Symptoms, Diagnosis and Treatment MAC00031-01 Rev G Financial support for this seminar has been provided by NeoTract, Inc., the manufacturer of the UroLift System. 1 Today s Agenda
More informationCharles E. Stoopack M.D. FACOG
Charles E. Stoopack M.D. FACOG 3240 Venado St! Carlsbad, CA 92009 Phone: 760-845-1692! Fax: 760-944-1333! E-Mail: cstoopack@ucsd.edu Education M.D. New York Medical College, Valhalla, N.Y., 1980 Michaelin
More informationCURRICULUM VITAE Robert Brannigan, M.D. Revised : 04/01
CURRICULUM VITAE Robert Brannigan, M.D. Revised : 04/01 CURRICULUM VITAE Robert Brannigan, M.D. Address The Center for Human Reproduction 60 East Delaware Place The Annex to the 900 North Michigan Building
More informationThe Centre for Men s Health
96 Harley Street (London) and Manchester All Enquiries - +44 (0)20 7486 2277 www.centreformenshealth.co.uk/ This leaflet provides information about: The Centre for Men s Health The conditions we treat:
More informationMMM. Topic The use of Tadalafil 5mg daily for the treatment of BPH-LUTS
Dr Tan & Partners MMM Vol. 1 No. 1 Morbidity & Mortality Meeting 14 th November 2014 Introduction Topic The use of Tadalafil 5mg daily for the treatment of BPH-LUTS Tadalafil 5mg daily is a well established
More informationProstate cancer. Treatments Side effects and management in the community setting
Prostate cancer Treatments Side effects and management in the community setting Kristoffer Ohlin CNS Urology Janice Minter Lead Cancer Nurse St George s Hospital Agenda Prostate cancer treatments Radiotherapy
More informationLower Urinary Tract Infection (UTI) in Males
Lower Urinary Tract Infection (UTI) in Males Clinical presentation For patients in care homes see UTI in adults where IV Antibiotics in the community may be appropriate (under development) History and
More informationCURRICULUM VITAE. S. Duke Herrell, M.D.
CURRICULUM VITAE S. Duke Herrell, M.D. OFFICE ADDRESS: Department of Urologic Surgery Vanderbilt University Medical Center A-1302, Medical Center North Nashville, TN 37232-2765 Phone: (615)-322-2142 FAX:
More information4 th Year Urology Core Objectives Keith Rourke (Revised June 1, 2007)
4 th Year Urology Core Objectives Keith Rourke (Revised June 1, 2007) I. Genitourinary Trauma: 1. Goal: The student will be able to demonstrate a basic clinical approach to the management & diagnosis of
More informationBPH: a present and future perspective on health impact
BPH: a present and future perspective on health impact Burden of disease in men with moderate LUTS Dalibor Pacík This presentation is financially supported by GlaxoSmithKline. CZ/DUTT/0019/12 Men with
More informationReport on New Patented Drugs - Vesicare
Report on New Patented Drugs - Vesicare Under its transparency initiative, the PMPRB publishes the results of the reviews of new patented drugs by Board Staff, for purposes of applying the Board's Excessive
More informationRole of herbal drugs in the management of benign prostatic hyperplasia: Clinical trial to evaluate the efficacy and safety of Himplasia
[Medicine Update (2003): 11(2), 55-58] Role of herbal drugs in the management of benign prostatic hyperplasia: Clinical trial to evaluate the efficacy and safety of Himplasia Arora, R.P., CMO, Rajiba L.
More informationObjectives. Prevalence of Urinary Incontinence URINARY INCONTINENCE: EVALUATION AND CURRENT TREATMENT OPTIONS
URINARY INCONTINENCE: EVALUATION AND CURRENT TREATMENT OPTIONS Lisa S Pair, MSN, CRNP Division of Urogynecology and Pelvic Reconstructive Surgery Department of Obstetrics and Gynecology University of Alabama
More informationChapter 18: Glossary
Chapter 18: Glossary Sutter Health Cancer Service Line: Prostate Committee Advanced cancer: When the cancer has spread to other parts of the body (including lymph nodes, bones, or other organs) and is
More informationCooled ThermoTherapy TM
Are BPH Medications Weighing You Down? Think Outside the Pillbox Cooled ThermoTherapy TM A non-surgical, 30 minute in-office treatment that provides long-term relief from BPH symptoms and urinary obstruction
More informationScott. A. Gasiorek, MD
Scott. A. Gasiorek, MD Certifications Board Certified June 1986 American Board of Radiology Therapeutic Radiology 1982 Diplomat of the National Board of Medical Examiners Licensure Georgia - #023600 (active)
More informationCanada Medtronic of Canada Ltd Kitimat Road Mississauga, Ontario L5N 1W3 Canada Tel Fax
What PATIENTS About TUNA Say Therapy TUNA THERAPY I would consider it to be a complete success. I have essentially no residual problems of any kind. I m back to the way I was before I ever had any symptoms
More informationDATE BIO# NAME: Last First Middle REFERRING PHYSICIAN NAME: REFERRING PHYSICIAN SPECIALTY (Urologist, Internist, etc.): PRIMARY CARE PHYSICIAN NAME:
DATE BIO# ERECTILE DYSFUNCTION QUESTIONNAIRE NAME: Last First Middle BIRTHDATE: OCCUPATION: REFERRING PHYSICIAN NAME: REFERRING PHYSICIAN SPECIALTY (Urologist, Internist, etc.): PRIMARY CARE PHYSICIAN
More informationSummary of Results for Laypersons
What was the Study Called? Summary of Results for Laypersons A Randomized, Double-blind, Parallel-group, Placebo- and Active-controlled, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability
More informationMITCHELL JAY RUBIN, M.D. FAAN (cell) Neurology Expert Witness Stroke tpa Emergency Neurology Telemedicine
Education University of Pennsylvania Philadelphia, Pennsylvania B. A. Summa Cum Laude 1976 Phi Beta Kappa 1977 Pi Gamma Mu (National Social Science Honor Society) 9/1977-5/1981 University of Pennsylvania
More informationTHE UROLOGY GROUP
THE UROLOGY GROUP www.urologygroupvirginia.com 1860 Town Center Drive Suite 150/160 Reston, VA 20190 703-480-0220 19415 Deerfield Avenue Suite 112 Leesburg, VA 20176 703-724-1195 224-D Cornwall Street,
More informationNeurogenic bladder. Neurogenic bladder is a type of dysfunction of the bladder due to neurological disorder.
Definition: Neurogenic bladder Neurogenic bladder is a type of dysfunction of the bladder due to neurological disorder. Types: Nervous system diseases: Congenital: like myelodysplasia like meningocele.
More informationMale LUTS, OAB, Sex: natural history. JR Sathiya
Male LUTS, OAB, Sex: natural history JR Sathiya Definitions Newer concepts of LUTs Natural history of BPH Prevalence of LUTs Definition BPH- represents a histologic diagnosis that refers to the proliferation
More informationUTI IN ELDERLY. Zeinab Naderpour
UTI IN ELDERLY Zeinab Naderpour Urinary tract infection (UTI) is the most frequent bacterial infection in elderly populations. While urinary infection in the elderly person is usually asymptomatic, symptomatic
More informationManaging urinary morbidity after brachytherapy. Kieran O Flynn Department of Urology, Salford Royal Foundation Trust, Manchester
Managing urinary morbidity after brachytherapy Kieran O Flynn Department of Urology, Salford Royal Foundation Trust, Manchester Themes Can we predict urinary morbidity? Prevention of urinary morbidity
More informationCurriculum Vitae, Joseph J. Savon, M.D.
CONTACT INFORMATION: Joseph J. Savon, M.D. Hassman Research Institute, LLC. 175 Cross Keys Road Centennial Center, Bldg. 300 B Berlin, NJ 08009 Site Selection and Information: Bobbie Theodore, Alliance
More informationCurriculum Vitae, Michael J. Downing, M.D.
CONTACT INFORMATION: Site Selection and Information: Bobbie Theodore, Alliance Director Tel. (916) 939-6696 Fax (208) 575-3169 Email: clinicaltrials@alliancesites.com PROFESSIONAL AFFILIATIONS: Michael
More informationGuidelines for the Management of Prostate Cancer West Midlands Expert Advisory Group for Urological Cancer
Guidelines for the Management of Prostate Cancer West Midlands Expert Advisory Group for Urological Cancer West Midlands Clinical Networks and Clinical Senate Coversheet for Network Expert Advisory Group
More informationAnatomical and Functional Results of Pelvic Organ Prolapse Mesh Repair: A Prospective Study of 105 Cases
International Journal of Clinical Urology 2018; 2(1): 20-24 http://www.sciencepublishinggroup.com/j/ijcu doi: 10.11648/j.ijcu.20180201.14 Anatomical and Functional Results of Pelvic Organ Prolapse Mesh
More informationNew Treatment Modalities for Benign Prostatic Hyperplasia. Seung-June Oh, MD Department of Urology, Seoul National University Hospital
New Treatment Modalities for Benign Prostatic Hyperplasia Seung-June Oh, MD Department of Urology, Seoul National University Hospital Options for Treating BPH Pharmacotherapy blocker Agents for BPH + OAB
More informationRITE Thermochemotherapy in the treatment of BCG refractory NMIBC
RITE Thermochemotherapy in the treatment of BCG refractory NMIBC Ben Ayres Consultant Urological Surgeon St George s Hospital London 1 Financial and Other Disclosures Off-label use of drugs, devices, or
More informationGUIDELINES ON. Introduction. G.R. Dohle, S. Arver, C. Bettocchi, S. Kliesch, M. Punab, W. de Ronde
GUIDELINES ON Male Hypogonadism G.R. Dohle, S. Arver,. Bettocchi, S. Kliesch, M. Punab, W. de Ronde Introduction Male hypogonadism is a clinical syndrome caused by androgen deficiency. It may adversely
More informationOveractive bladder syndrome (OAB)
Service: Urology Overactive bladder syndrome (OAB) Exceptional healthcare, personally delivered What is OAB? An overactive bladder or OAB is where a person regularly gets a sudden and compelling need or
More informationLearning Objectives. Peri menopause. Menopause Overview. Recommendation grading categories
Learning Objectives Identify common symptoms of the menopause transition Understand the risks and benefits of hormone replacement therapy (HRT) Be able to choose an appropriate hormone replacement regimen
More informationProstate Cancer Dashboard
Process Risk Assessment Risk assessment: family history assessment of family history of prostate cancer Best Observed: 97 %1 ; Ideal Benchmark:100% measure P8 2 Process Appropriateness of Care Pre-treatment
More informationDr. Aso Urinary Symptoms
Haematuria The presence of blood in the urine (haematuria) is always abnormal and may be the only indication of pathology in the urinary tract. False positive stick tests and the discolored urine caused
More informationShandra Sheppard Wilson, M.D. Assistant Professor, Division of Urology Objective: Education: Achievements:
Shandra Sheppard Wilson, M.D. Assistant Professor, Division of Urology 4200 East Ninth Avenue, Box C-319 Denver, Colorado 80220 303-315-8972 (P) 303-315-7611 (F) shandra.wilson@uchsc.edu Objective: To
More informationOpen clinical uro-oncology trials in Canada George Rodrigues, MD, Mary J. Mackenzie, MD, Eric Winquist, MD
Open clinical uro-oncology trials in Canada George Rodrigues, MD, Mary J. Mackenzie, MD, Eric Winquist, MD London Health Sciences Centre, London, Ontario, Canada BLADDER CANCER A MULTICENTRE, RANDOMIZED
More informationClinical AMG - Studies as Principal Investigator since 2009
Clinical Study Experience Dr. Susan Feyerabend Clinical AMG - Studies as LKP since 2009 2009 Extension study of Degarelix versus Goserelin in hormone-naive prostate cancer patients, phase III 2015 Randomized,
More informationThe Urinary System. Maintenance Systems Unit 5
The Urinary System Maintenance Systems Unit 5 Basic Functions of the Urinary System Regulates the composition and volume of the blood by removing and restoring selected amounts of water and solutes. Eliminates
More informationCialis. Cialis (tadalafil) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.06.02 Subject: Cialis Page: 1 of 5 Last Review Date: September 18, 2015 Cialis Description Cialis (tadalafil)
More informationAbiraterone Acetate is an antiandrogen used in the treatment of Castration-Resistant Prostate Cancer(CRPC).
For the use only of an Oncologist or a Hospital or a Laboratory ABIRATERONE ACETATE TABLETS Zabiteron-250 COMPOSITION Abiraterone Acetate Tablets 250mg Each uncoated tablets contains: Abiraterone Acetate
More informationManagement of LUTS after TURP and MIT
Management of LUTS after TURP and MIT Hong Sup Kim Konkuk University TURP & MIT TURP : Gold standard MIT TUIP TUNA TUMT HIFU LASER Nd:YAG, ILC, HoLRP, KTP LUTS after TURP and MIT Improved : about 70% Persistent
More informationOveractive Bladder Syndrome
Overactive Bladder Syndrome behavioural modifications to pharmacological and surgical treatments Dr Jos Jayarajan Urologist Austin Health, Eastern Health Warringal Private, Northpark Private, Epworth Overactive
More informationScreening for Prostate Cancer with the Prostate Specific Antigen (PSA) Test: Recommendations 2014
Screening for Prostate Cancer with the Prostate Specific Antigen (PSA) Test: Recommendations 2014 Canadian Task Force on Preventive Health Care October 2014 Putting Prevention into Practice Canadian Task
More informationSELECTED POSTER PRESENTATIONS
SELECTED POSTER PRESENTATIONS The following summaries are based on posters presented at the American Urogynecological Society 2004 Scientific Meeting, held July 29-31, 2004, in San Diego, California. CENTRAL
More informationOveractive bladder (OAB) affects approximately 15% of the adult population. Diagnosis is based
Overactive bladder (OAB) affects approximately 15% of the adult population. Diagnosis is based upon a medical history, and includes a focused physical exam (abdominal, neurological, pelvic in females and
More informationComparison of Symptom Severity and Treatment Response in Patients with Incontinent and Continent Overactive Bladder
European Urology European Urology 48 (2005) 110 115 Female UrologyöIncontinence Comparison of Symptom Severity and Treatment Response in Patients with Incontinent and Continent Overactive Bladder Martin
More informationOpen clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD
CLINICAL TRIALS Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer A PHASE II PROTOCOL FOR PATIENTS
More informationDiagnosis and Mangement of Nocturia in Adults
Diagnosis and Mangement of Nocturia in Adults Christopher Chapple Professor of Urology Sheffield Teaching Hospitals University of Sheffield Sheffield Hallam University UK 23 rd October 2015 Terminology
More informationURODYNAMICS Welcome to Chesapeake Urology s Urodynamics Services. Bladder control problems keep millions of people from enjoying a full life, but today, many treatments are available to help. To assist
More informationLaser vaporisation of prostate (Green light laser prostate surgery): procedure-specific information
PATIENT INFORMATION Laser vaporisation of prostate (Green light laser prostate surgery): procedure-specific information What is the evidence base for this information? This leaflet includes advice from
More informationJulie M. Krupa. University of South Florida, Department of Criminology 4202 East Fowler Ave, Tampa FL Phone:
Julie M. Krupa Contact Office:, Department of Criminology 4202 East Fowler Ave, Tampa FL 33620 Email: jkrupa1@mail.usf.edu Phone: 810-964-2620 Education 2018 PhD in Criminology, (expected) Dissertation:
More information*Compounds with "In-house" in this column include ones discovered by collaborative research.
AGS67E Lymphoid malignancies P-I Injection In-house (ADC technology in-licensed from Seattle Genetics) AGS62P1 Acute myeloid leukemia P-I Injection In-house (ADC technology, EuCODE license from Ambrx)
More informationDouglas N. Robins, M.D. Ameriderm Research
Curriculum Vitae Douglas N. Robins, M.D. Ameriderm Research Office Address: Leavitt Medical Associates of Florida (DBA) Advanced Dermatology and Cosmetic Surgery Ameriderm Research 4100 Southpoint Dr.
More informationIntravesical immunotherapy (known as BCG therapy): procedure-specific information
PATIENT INFORMATION Intravesical immunotherapy (known as BCG therapy): procedure-specific information What is the evidence base for this information? This leaflet includes advice from consensus panels,
More information